Total raised
$25.0M
Last: PIPE 2026-02
Stage
Public
Founded
2019
Headcount
6
HQ
Tel Aviv-Yafo
Sector
Health Tech & Life Sciences
About
Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations (such as opioid overdose and anaphylactic shock) based on its microsphere technology. Nasus's portfolio comprises a number of programs including intranasal naloxone, intranasal epinephrine, and a number of preclinical proof-of-concept programs.
Funding history · 1 round · $25.0M total
2026-02
PIPE
$15.0M
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Nasus Pharma go public and on what exchange?
- Nasus Pharma completed its Initial Public Offering (IPO) in August 2025, listing on the NYSE American exchange with a valuation of $75 million.
- What was the outcome of Nasus Pharma's Phase 2 clinical study for NS002 Intranasal Epinephrine Powder?
- In March 2026, Nasus Pharma announced positive top-line data from its Phase 2 clinical study of NS002, demonstrating significantly superior and faster epinephrine delivery compared to EpiPen® with an accelerated speed to therapeutic threshold.
- What was the most recent funding event for Nasus Pharma?
- In February 2026, Nasus Pharma closed a $15.0 million private placement (PIPE) round of funding.
- What is the primary focus of Nasus Pharma's product development?
- Nasus Pharma is developing intranasal powder products based on its microsphere technology, aimed at assisting patients in acute emergency situations such as opioid overdose and anaphylactic shock. Their portfolio includes intranasal naloxone (NS-001) and intranasal epinephrine (NS-002).
- When was Nasus Pharma founded and where is its headquarters located?
- Nasus Pharma was founded in May 2019 and is headquartered in Tel Aviv-Yafo, Israel.
- What was a notable leadership team appointment at Nasus Pharma in late 2025?
- In November 2025, Nasus Pharma strengthened its leadership team by appointing Eyal Rubin as Executive Vice President and Chief Financial Officer.
- What was the status of Nasus Pharma's NS002 program in November 2025?
- In November 2025, Nasus Pharma announced the initiation of the Phase 2 clinical study for NS002, with the first participant dosed, following approval from Health Canada.
- What was the market capitalization of Nasus Pharma as of January 2026?
- As of January 1, 2026, Nasus Pharma had a market capitalization of $82,895,651 USD.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B2C
Highlights
1 Patents
Tags
drug-deliverynon-invasivemedical-technologiesemergency-responsepharmaceuticalstreatmentsrespiratorybiopharmaceuticalinhalationbacteriamedical-devicespublic-health